摘要
目的评价格列吡嗪控释片（瑞易宁）治疗2型糖尿病的有效性、安全性。方法为多中心、开放性临床观察性研究。675例患者完成了本研究。对单纯生活方式干预（n=134）或已用非胰岛素促泌剂（n=305）治疗，但血糖控制不佳的患者，加用瑞易宁；对已用其他磺脲类或格列奈类促泌剂（n=236）治疗，但血糖控制不佳、安全性不好或生活质量受影响的患者，停用原促泌剂，改用瑞易宁。瑞易宁治疗12周后，评价其有效性、安全性和对生活质量的影响。结果应用瑞易宁治疗后，糖化血红蛋白（Hb）Alc下降（1．48±1．20）％，空腹血糖下降（2．47±1．38）mmol／L，餐后血糖下降（3．64±2．63）mmol／L（P值均为0．0000）；52．21％的患者HbAlc〈6．5％，83．21％的患者HbAlc〈7．0％。治疗期间轻度低血糖发生率为4．59％，严重低血糖发生率为0．15％。原促泌剂治疗组改用瑞易宁后低血糖显著减少，99％以上的患者认为瑞易宁较其他促泌剂更为简单易行，生活质量提高，更愿意选用瑞易宁治疗。结论在2型糖尿病治疗中，瑞易宁为一疗效显著、安全性好、能提高患者生活质量的口服降糖药，可广泛用于临床。
Objective To investigate the effect and safety of glipizide GITS in the therapy of type 2 diabetes. Methods A total of 675 type 2 diabetic patients were included in this multi-center,open-labeled and self-controlled clinical study. Patients with inadequate glycemic control by life style intervention （n = 134 ）or non-insulin seeretagogues（ n = 305 ）were added glipizide GITS therapy for 12 weeks. Patients with inadequate glycemic control, poor safety or low life quality by other secretagogues （n = 236 ）were changed to glipizide GITS therapy for 12 weeks. Results After treatment by glipizide GITS, HhA1 c of these patients decreased （ 1.48 ± 1.20 ） % （ P = 0. 0000 ） , fasting blood glucose decreased （ 2.47 ± 1.38 ） mmol/L （ P = 0. 0000 ） , postprandial blood glucose decreased （3.64 ± 2.63 ） mmol/L （ P = 0. 0000）. 52.21% patients obtained the target of HbAlc 〈 6.5% ,83.21% obtained the target of HbAlc 〈 7.0%. The incidence of mild and serious hypoglycemia were 4.59% and 0.15% respectively. In patients transferred from other insulin secretagogues to glipizide GITS, 99% preferred glipizide GITS for its convenience and beneficial for life quality improvement. Conclusion Glipizide GITS is an evidently effective and safe oral hypoglycemic agents, and is beneficial to life quality improvement for type 2 diabetic patients. Therefore it can be used widely in clinic.
出处
《国际内分泌代谢杂志》
2011年第2期73-76,共4页
International Journal of Endocrinology and Metabolism
关键词
2型糖尿病
口服降糖药
瑞易宁
Type 2 diabetes mellitus
Oral hypoglycemic agents
Glipizide GITS
